Thalomide

This page contains recent news articles, when available, and an overview of Thalomide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Thalidomide OK'd as multiple myeloma treatment  -  May 26, 2006
Because the drug was linked several decades ago to severe birth defects, Thalomide is prescribed through a stringent system that requires women of ... Pay-Per-View - The Record - Factiva, from Dow Jones

Vaccine about cash, not health  -  Sep 25, 2007
Recall thalomide; the tainted blood scandal; the link between the flu shot containing thermosal (50 per cent ethylmercury) and the skyrocketing autism in ... Prince George Citizen

Once-Condemned Drug May Control Blood Cancer  -  Jan 24, 2006
In fact, the thalomide-dexamethasone combination held the cancer in check for more than 75 weeks on average, as compared to fewer than 30 weeks in patients ... Health Video

La UE aprueba su huérfano número 50 y augura un buen futuro al área  -  Nov 17, 2008
Los fármacos huérfanos aprobados en 2008 son Thalomide Pharmion (talidomida, de Pharmion), para el tratamiento del mieloma múltiple; Volibris (ambrisentan, ... Correo Farmacéutico

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.